Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial

Archive ouverte

Tao, Y. | Biau, J. | Sun, X.S. | Sire, C. | Martin, L. | Alfonsi, M. | Prevost, J.B. | Modesto, A. | Lafond, C. | Tourani, J.M. | Miroir, J. | Kaminsky, M.C. | Coutte, Alexandre | Liem, X. | Chautard, E. | Vauleon, E. | Drouet, F. | Ruffier, A. | Ramee, J.F. | Waksi, G. | Péchery, A. | Wanneveich, M. | Guigay, J. | Aupérin, A. | Bourhis, J.

Edité par CCSD ; Elsevier -

International audience. To evaluate potential synergistic effect of pembrolizumab with radiotherapy (RT) compared with a standard-of-care (SOC) cetuximab-RT in patients with locally advanced-squamous cell carcinoma of head and neck (LA-SCCHN).

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion